GB0612721D0 - Organic compounds - Google Patents

Organic compounds

Info

Publication number
GB0612721D0
GB0612721D0 GBGB0612721.1A GB0612721A GB0612721D0 GB 0612721 D0 GB0612721 D0 GB 0612721D0 GB 0612721 A GB0612721 A GB 0612721A GB 0612721 D0 GB0612721 D0 GB 0612721D0
Authority
GB
United Kingdom
Prior art keywords
organic compounds
amino
neo
diol
propane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0612721.1A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36888144&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GB0612721(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Priority to GBGB0612721.1A priority Critical patent/GB0612721D0/en
Publication of GB0612721D0 publication Critical patent/GB0612721D0/en
Priority to KR1020177034918A priority patent/KR20170138583A/ko
Priority to DK15177166.4T priority patent/DK2959894T3/da
Priority to RU2013131176/15A priority patent/RU2569732C9/ru
Priority to US12/303,765 priority patent/US20100168078A1/en
Priority to RU2009102278A priority patent/RU2617502C2/ru
Priority to EP07764828A priority patent/EP2037906A1/en
Priority to DE15177166.4T priority patent/DE15177166T1/de
Priority to PL15177166.4T priority patent/PL2959894T3/pl
Priority to ES15177166T priority patent/ES2887042T3/es
Priority to LTEP2959894T priority patent/LT2959894T/lt
Priority to SI200732191T priority patent/SI2959894T1/sl
Priority to KR1020217001928A priority patent/KR20210010956A/ko
Priority to EP15177166.4A priority patent/EP2959894B1/en
Priority to JP2009516964A priority patent/JP2009541386A/ja
Priority to PCT/EP2007/005597 priority patent/WO2008000419A1/en
Priority to EP13186359.9A priority patent/EP2698154A1/en
Priority to AU2007264031A priority patent/AU2007264031C1/en
Priority to CN2007800236012A priority patent/CN101478961B/zh
Priority to HUE15177166A priority patent/HUE059922T4/hu
Priority to KR1020147010290A priority patent/KR20140069178A/ko
Priority to PT151771664T priority patent/PT2959894T/pt
Priority to KR1020197007465A priority patent/KR20190030776A/ko
Priority to CN201310446846.3A priority patent/CN103550195A/zh
Priority to KR1020157030213A priority patent/KR20150122812A/ko
Priority to EP20208442.2A priority patent/EP3797765A1/en
Priority to MX2008016133A priority patent/MX2008016133A/es
Priority to BRPI0713985-3A priority patent/BRPI0713985A2/pt
Priority to KR1020097001390A priority patent/KR20090024281A/ko
Priority to CA2653569A priority patent/CA2653569C/en
Priority to MX2019012750A priority patent/MX2019012750A/es
Priority to MX2022008950A priority patent/MX2022008950A/es
Priority to AU2011201844A priority patent/AU2011201844B2/en
Priority to US13/149,468 priority patent/US8741963B2/en
Priority to AU2013200356A priority patent/AU2013200356B2/en
Priority to JP2013076909A priority patent/JP2013166761A/ja
Priority to US14/257,342 priority patent/US9187405B2/en
Priority to HK16102706.3A priority patent/HK1214758B/en
Priority to JP2016087703A priority patent/JP2016185957A/ja
Priority to AU2016266058A priority patent/AU2016266058A1/en
Priority to JP2018021389A priority patent/JP2018109018A/ja
Priority to AU2018202210A priority patent/AU2018202210A1/en
Priority to JP2019089217A priority patent/JP6931019B2/ja
Priority to AU2019219818A priority patent/AU2019219818A1/en
Priority to JP2020176666A priority patent/JP7258832B2/ja
Priority to AU2021202395A priority patent/AU2021202395A1/en
Priority to JP2023061697A priority patent/JP2023098949A/ja
Priority to JP2024172795A priority patent/JP2025016462A/ja
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
    • C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
    • C07C215/08—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with only one hydroxy group and one amino group bound to the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
GBGB0612721.1A 2006-06-27 2006-06-27 Organic compounds Ceased GB0612721D0 (en)

Priority Applications (48)

Application Number Priority Date Filing Date Title
GBGB0612721.1A GB0612721D0 (en) 2006-06-27 2006-06-27 Organic compounds
KR1020177034918A KR20170138583A (ko) 2006-06-27 2007-06-25 다발성 경화증 치료용 ｓ１ｐ 수용체 조절제
DK15177166.4T DK2959894T3 (da) 2006-06-27 2007-06-25 S1p-receptormodulatorer til behandling af multipel sklerose
RU2013131176/15A RU2569732C9 (ru) 2006-06-27 2007-06-25 Модуляторы рецептора s1p для лечения рассеянного склероза
US12/303,765 US20100168078A1 (en) 2006-06-27 2007-06-25 S1p receptor modulators for treating multiple sclerosis
RU2009102278A RU2617502C2 (ru) 2006-06-27 2007-06-25 Модуляторы рецептора s1p для лечения рассеянного склероза
EP07764828A EP2037906A1 (en) 2006-06-27 2007-06-25 S1p receptor modulators for treating multiple sclerosis
DE15177166.4T DE15177166T1 (de) 2006-06-27 2007-06-25 S1p-rezeptormodulatoren für die behandlung von multipler sklerose
PL15177166.4T PL2959894T3 (pl) 2006-06-27 2007-06-25 Modulatory receptora s1p do leczenia stwardnienia rozsianego
ES15177166T ES2887042T3 (es) 2006-06-27 2007-06-25 Moduladores del receptor S1P para el tratamiento de la esclerosis múltiple
LTEP2959894T LT2959894T (lt) 2006-06-27 2007-06-25 S1p receptoriaus moduliatoriai, skirti išsėtinės sklerozės gydymui
SI200732191T SI2959894T1 (sl) 2006-06-27 2007-06-25 S1P receptorski modulatorji za zdravljenje multiple skleroze
KR1020217001928A KR20210010956A (ko) 2006-06-27 2007-06-25 다발성 경화증 치료용 ｓ１ｐ 수용체 조절제
EP15177166.4A EP2959894B1 (en) 2006-06-27 2007-06-25 S1p receptor modulators for treating multiple sclerosis
JP2009516964A JP2009541386A (ja) 2006-06-27 2007-06-25 多発性硬化症を処置するためのｓ１ｐ受容体モジュレーター
PCT/EP2007/005597 WO2008000419A1 (en) 2006-06-27 2007-06-25 S1p receptor modulators for treating multiple sclerosis
EP13186359.9A EP2698154A1 (en) 2006-06-27 2007-06-25 S1P receptor modulators for treating multiple sclerosis
AU2007264031A AU2007264031C1 (en) 2006-06-27 2007-06-25 S1P receptor modulators for treating multiple sclerosis
CN2007800236012A CN101478961B (zh) 2006-06-27 2007-06-25 用于治疗多发硬化症的s1p受体调节剂
HUE15177166A HUE059922T4 (hu) 2006-06-27 2007-06-25 S1 receptor modulátorok sclerosis multiplex kezelésére
KR1020147010290A KR20140069178A (ko) 2006-06-27 2007-06-25 다발성 경화증 치료용 ｓ１ｐ 수용체 조절제
PT151771664T PT2959894T (pt) 2006-06-27 2007-06-25 Modulador de um receptor de s1p para o tratamento de esclerose múltipla
KR1020197007465A KR20190030776A (ko) 2006-06-27 2007-06-25 다발성 경화증 치료용 ｓ１ｐ 수용체 조절제
CN201310446846.3A CN103550195A (zh) 2006-06-27 2007-06-25 用于治疗多发硬化症的s1p受体调节剂
KR1020157030213A KR20150122812A (ko) 2006-06-27 2007-06-25 다발성 경화증 치료용 ｓ１ｐ 수용체 조절제
EP20208442.2A EP3797765A1 (en) 2006-06-27 2007-06-25 S1p receptor modulators for treating multiple sclerosis
MX2008016133A MX2008016133A (es) 2006-06-27 2007-06-25 Moduladores del receptor s1p para el tratamiento de esclerosis multiple.
BRPI0713985-3A BRPI0713985A2 (pt) 2006-06-27 2007-06-25 compostos orgÂnicos
KR1020097001390A KR20090024281A (ko) 2006-06-27 2007-06-25 다발성 경화증 치료용 ｓ１ｐ 수용체 조절제
CA2653569A CA2653569C (en) 2006-06-27 2007-06-25 S1p receptor modulators for treating multiple sclerosis
MX2019012750A MX2019012750A (es) 2006-06-27 2008-12-16 Moduladores del receptor s1p para el tratamiento de esclerosis multiple.
MX2022008950A MX2022008950A (es) 2006-06-27 2008-12-16 Moduladores del receptor s1p para el tratamiento de esclerosis multiple.
AU2011201844A AU2011201844B2 (en) 2006-06-27 2011-04-21 S1P receptor modulators for treating multiple sclerosis
US13/149,468 US8741963B2 (en) 2006-06-27 2011-05-31 S1P receptor modulators for treating multiple sclerosis
AU2013200356A AU2013200356B2 (en) 2006-06-27 2013-01-24 S1P receptor modulators for treating multiple sclerosis
JP2013076909A JP2013166761A (ja) 2006-06-27 2013-04-02 多発性硬化症を処置するためのｓ１ｐ受容体モジュレーター
US14/257,342 US9187405B2 (en) 2006-06-27 2014-04-21 S1P receptor modulators for treating relasping-remitting multiple sclerosis
HK16102706.3A HK1214758B (en) 2006-06-27 2014-05-02 S1p receptor modulators for treating multiple sclerosis
JP2016087703A JP2016185957A (ja) 2006-06-27 2016-04-26 多発性硬化症を処置するためのｓ１ｐ受容体モジュレーター
AU2016266058A AU2016266058A1 (en) 2006-06-27 2016-12-01 S1P receptor modulators for treating multiple sclerosis
JP2018021389A JP2018109018A (ja) 2006-06-27 2018-02-08 多発性硬化症を処置するためのｓ１ｐ受容体モジュレーター
AU2018202210A AU2018202210A1 (en) 2006-06-27 2018-03-28 S1P receptor modulators for treating multiple sclerosis
JP2019089217A JP6931019B2 (ja) 2006-06-27 2019-05-09 多発性硬化症を処置するためのｓ１ｐ受容体モジュレーター
AU2019219818A AU2019219818A1 (en) 2006-06-27 2019-08-22 S1P receptor modulators for treating multiple sclerosis
JP2020176666A JP7258832B2 (ja) 2006-06-27 2020-10-21 多発性硬化症を処置するためのｓ１ｐ受容体モジュレーター
AU2021202395A AU2021202395A1 (en) 2006-06-27 2021-04-20 S1P receptor modulators for treating multiple sclerosis
JP2023061697A JP2023098949A (ja) 2006-06-27 2023-04-05 多発性硬化症を処置するためのｓ１ｐ受容体モジュレーター
JP2024172795A JP2025016462A (ja) 2006-06-27 2024-10-01 多発性硬化症を処置するためのｓ１ｐ受容体モジュレーター

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0612721.1A GB0612721D0 (en) 2006-06-27 2006-06-27 Organic compounds

Publications (1)

Publication Number Publication Date
GB0612721D0 true GB0612721D0 (en) 2006-08-09

Family

ID=36888144

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0612721.1A Ceased GB0612721D0 (en) 2006-06-27 2006-06-27 Organic compounds

Country Status (20)

Country Link
US (3) US20100168078A1 (enExample)
EP (4) EP2698154A1 (enExample)
JP (8) JP2009541386A (enExample)
KR (6) KR20150122812A (enExample)
CN (2) CN101478961B (enExample)
AU (7) AU2007264031C1 (enExample)
BR (1) BRPI0713985A2 (enExample)
CA (1) CA2653569C (enExample)
DE (1) DE15177166T1 (enExample)
DK (1) DK2959894T3 (enExample)
ES (1) ES2887042T3 (enExample)
GB (1) GB0612721D0 (enExample)
HU (1) HUE059922T4 (enExample)
LT (1) LT2959894T (enExample)
MX (3) MX2008016133A (enExample)
PL (1) PL2959894T3 (enExample)
PT (1) PT2959894T (enExample)
RU (1) RU2617502C2 (enExample)
SI (1) SI2959894T1 (enExample)
WO (1) WO2008000419A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0612721D0 (en) * 2006-06-27 2006-08-09 Novartis Ag Organic compounds
KR101526835B1 (ko) * 2007-05-04 2015-06-05 노파르티스 아게 Ｓ1ｐ 수용체 조절제의 용도
SG10201406263SA (en) * 2008-06-20 2015-02-27 Novartis Ag Paediatric compositions for treating multiple sclerosis
RU2523281C2 (ru) * 2008-08-18 2014-07-20 Новартис Аг Соединения для лечения периферических невропатий
EP2177521A1 (en) 2008-10-14 2010-04-21 Almirall, S.A. New 2-Amidothiadiazole Derivatives
KR20170062554A (ko) * 2008-12-18 2017-06-07 노파르티스 아게 1-［4-［1-(4-시클로헥실-3-트리플루오로메틸-벤질옥시이미노)-에틸］-2-에틸-벤질］-아제티딘-3-카르복실산의 헤미푸마레이트 염
RU2011129230A (ru) * 2008-12-18 2013-01-27 Новартис Аг Новая полиморфная форма 1-[4-[1-(4-циклогексил-3-трифторметилбензилоксиимино)этил]-2-этилбензил]азетидин-3-карбоновой кислоты
CN103204794A (zh) * 2008-12-18 2013-07-17 诺瓦提斯公司 新的盐
EP2202232A1 (en) 2008-12-26 2010-06-30 Laboratorios Almirall, S.A. 1,2,4-oxadiazole derivatives and their therapeutic use
EP2210890A1 (en) 2009-01-19 2010-07-28 Almirall, S.A. Oxadiazole derivatives as S1P1 receptor agonists
EP2305660A1 (en) 2009-09-25 2011-04-06 Almirall, S.A. New thiadiazole derivatives
US20110124605A1 (en) * 2009-11-20 2011-05-26 Shreeram Aradhye Use of an S1P Receptor Agonist
RU2012125184A (ru) * 2009-11-24 2013-12-27 Аллерган, Инк. Новые соединения в качестве модуляторов рецепторов с терапевтическим действием
EP2343287A1 (en) 2009-12-10 2011-07-13 Almirall, S.A. New 2-aminothiadiazole derivatives
EP2366702A1 (en) 2010-03-18 2011-09-21 Almirall, S.A. New oxadiazole derivatives
EP2390252A1 (en) 2010-05-19 2011-11-30 Almirall, S.A. New pyrazole derivatives
BR112013017302B1 (pt) 2011-01-07 2021-12-07 Novartis Ag Composição farmacêutica em fase sólida
CN102120720B (zh) * 2011-01-25 2013-05-22 上海华升生物科技有限公司 盐酸芬戈莫德的合成新方法
MX2014004813A (es) * 2011-10-21 2014-05-20 Novartis Ag Regimen de dosificacion para un modulador o agonista del receptor s1p.
EP2830338A4 (en) * 2012-03-23 2015-12-30 Nec Corp SUBSCRIBER SERVER, MONITOR SERVER, MOBILE TERMINAL, ASSOCIATED METHOD AND COMPUTER READABLE MEDIUM
RU2506949C1 (ru) * 2012-06-13 2014-02-20 Открытое акционерное общество "Новосибхимфарм" Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний
CN102887829B (zh) * 2012-09-05 2014-07-02 中国科学院上海药物研究所 芬戈莫德粘酸盐及其晶体的制备方法和用途
WO2015053878A1 (en) 2013-10-11 2015-04-16 Teikoku Pharma Usa, Inc. Topical sphingosine-1-phosphate receptor agonist formulations and methods of using the same
US10675254B2 (en) 2013-10-11 2020-06-09 Teikoku Seiyaku Co., Ltd. Sphingosine-1-phosphate receptor agonist iontophoretic devices and methods of using the same
US20180042895A1 (en) 2015-02-26 2018-02-15 Novartis Ag Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
WO2017120124A1 (en) 2016-01-04 2017-07-13 Auspex Pharmaceuticals, Inc. Azetidine modulators of the sphingosine 1-phosphate receptor
US11434200B2 (en) 2017-03-09 2022-09-06 Novartis Ag Solid forms comprising an oxime ether compound and a coformer, compositions and methods of use thereof
US11629124B2 (en) 2017-03-09 2023-04-18 Novartis Ag Solid forms comprising an oxime ether compound, compositions and methods of use thereof
PH12022551043A1 (en) 2019-10-31 2023-05-03 Idorsia Pharmaceuticals Ltd Combination of a cxcr7 antagonist with an s1p1 receptor modulator
US20250177115A1 (en) * 2021-08-20 2025-06-05 The Brain Protection Company PTY LTD Combinatorial therapies including implantable damping devices and therapeutic agents for treating a condition and associated systems and methods of use
EP4212156A1 (en) 2022-01-13 2023-07-19 Abivax Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a s1p receptor modulator

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB612721A (en) 1946-02-11 1948-11-17 Richard William Bailey Improvements in combustion product power plant
DE122011100012I1 (de) 1992-10-21 2011-10-20 Mitsubishi Tanabe Pharma Corp 2-Amino-1, 3-propandiolverbindung und immunosuppressium.
ATE348110T1 (de) 1992-10-28 2007-01-15 Genentech Inc Hvegf rezeptor als vegf antagonist
WO1996006068A1 (en) 1994-08-22 1996-02-29 Yoshitomi Pharmaceutical Industries, Ltd. Benzene compound and medicinal use thereof
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
DE19638745C2 (de) 1996-09-11 2001-05-10 Schering Ag Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR)
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
IL155065A (en) 1997-04-04 2004-01-04 Mitsubishi Pharma Corp History - 2 Aminopropene - 1, 3 - Diol and Pharmaceutical Preparations Containing Them
ATE459616T1 (de) 1998-08-11 2010-03-15 Novartis Ag Isochinoline derivate mit angiogenesis-hemmender wirkung
GB9824579D0 (en) 1998-11-10 1999-01-06 Novartis Ag Organic compounds
UA71587C2 (uk) 1998-11-10 2004-12-15 Шерінг Акцієнгезелльшафт Аміди антранілової кислоти та їхнє застосування як лікарських засобів
DE69926536T3 (de) 1998-12-22 2013-09-12 Genentech, Inc. Antagonisten von vaskular-endothelialen zellwachstumsfaktoren und ihre anwendung
CA2366857C (en) 1999-03-30 2010-12-14 Novartis Ag Phthalazine derivatives for treating inflammatory diseases
AR025068A1 (es) 1999-08-10 2002-11-06 Bayer Corp Pirazinas sustituidas y piridazinas fusionadas, composicion farmaceutica que las comprenden, uso de dichos compuestos para la manufactura de un medicamentocon actividad inhibidora de angiogenesis
GB0001930D0 (en) 2000-01-27 2000-03-22 Novartis Ag Organic compounds
AU2001231710A1 (en) 2000-02-09 2001-08-20 Novartis Ag Pyridine derivatives inhibiting angiogenesis and/or vegf receptor tyrosine kinase
DE10033541C2 (de) 2000-07-11 2003-05-15 Litef Gmbh Lichtleitfaserspule für ein faseroptisches Sagnac-Interferometer und Verfahren zu ihrer Herstellung
CN1267429C (zh) 2000-07-13 2006-08-02 三共株式会社 氨基醇衍生物
CA2421893A1 (en) 2000-08-31 2002-03-07 Merck And Co., Inc. Phosphate derivatives as immunoregulatory agents
RU2199339C2 (ru) 2001-02-23 2003-02-27 Общество с ограниченной ответственностью "Биотех" Способ лечения рассеянного склероза
JP2002316985A (ja) 2001-04-20 2002-10-31 Sankyo Co Ltd ベンゾチオフェン誘導体
WO2003062252A1 (en) 2002-01-18 2003-07-31 Merck & Co., Inc. Edg receptor agonists
DE60330047D1 (en) 2002-01-18 2009-12-24 Merck & Co Inc "n-(benzyl)aminoalkyl carboxylate, phosphinate, phosphonate und tetrazole als edg rezeptoragonisten"
ES2316758T3 (es) 2002-05-16 2009-04-16 Novartis Ag Uso de aglutinantes del receptor edg en el cancer.
EP1511473B8 (en) * 2002-05-27 2013-07-24 Novartis AG Bis-aromatic alkanols
TWI335311B (en) * 2002-09-24 2011-01-01 Novartis Ag Organic compounds
KR20040048231A (ko) * 2002-12-02 2004-06-07 주식회사 두산 신생혈관생성 억제제 및 그를 포함한 암 치료용 키트
FR2848495B1 (fr) * 2002-12-12 2006-11-17 Sidel Sa Four pour chauffer au defile des ebauches de recipients en materiau thermoplastique
KR101367574B1 (ko) 2003-04-08 2014-02-25 미쓰비시 타나베 파마 코퍼레이션 Ｓ1ｐ 수용체 아고니스트 및 당 알콜을 포함하는 고형 제약 조성물
PE20050158A1 (es) 2003-05-19 2005-05-12 Irm Llc Compuestos inmunosupresores y composiciones
JP4728962B2 (ja) * 2003-05-19 2011-07-20 アイアールエム・リミテッド・ライアビリティ・カンパニー 免疫抑制化合物および組成物
MY150088A (en) 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
UA74941C2 (en) 2004-04-26 2006-02-15 Fos Internat S A A metal-thermal process for producing magnesium and vacuum induction furnace for realizing the same
WO2005113330A1 (en) 2004-05-05 2005-12-01 Adler, Richard, S. Systems and methods for protecting ship from attack on the surface or under water
US7354580B2 (en) * 2004-06-10 2008-04-08 Regeneron Pharmaceuticals, Inc. Method of administering and using VEGF inhibitors for the treatment of human cancer
CN102397542B (zh) * 2004-11-18 2014-05-07 英克隆有限责任公司 抗血管内皮生长因子受体-1的抗体
KR20130041385A (ko) 2004-11-29 2013-04-24 노파르티스 아게 Ｓ１ｐ 수용체 효능제의 투여 용법
MX2007007165A (es) * 2004-12-17 2007-08-14 Genentech Inc Terapia de antiangiogenesis de enfermedad autoinmune en pacientes en quienes ha fallado la terapia anterior.
RU2278687C1 (ru) 2005-06-16 2006-06-27 Государственное образовательное учреждение высшего профессионального образования "БАШКИРСКИЙ ГОСУДАРСТВЕННЫЙ МЕДИЦИНСКИЙ УНИВЕРСИТЕТ ФЕДЕРАЛЬНОГО АГЕНТСТВА ПО ЗДРАВООХРАНЕНИЮ И СОЦИАЛЬНОМУ РАЗВИТИЮ" (ГОУ ВПО БГМУ РОСЗДРАВА РОССИИ) Способ лечения ремиттирующего рассеянного склероза
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
GB0612721D0 (en) 2006-06-27 2006-08-09 Novartis Ag Organic compounds
AU2009274512A1 (en) 2008-07-25 2010-01-28 The Regents Of The University Of Colorado Clip inhibitors and methods of modulating immune function
GB2527550B (en) 2014-06-25 2016-09-21 Cook Medical Technologies Llc Implantable medical device with lumen constriction

Also Published As

Publication number Publication date
ES2887042T3 (es) 2022-11-14
ES2887042T1 (es) 2021-12-21
KR20140069178A (ko) 2014-06-09
RU2013131176A (ru) 2015-01-20
KR20190030776A (ko) 2019-03-22
US20140228446A1 (en) 2014-08-14
CA2653569C (en) 2016-06-21
JP2016185957A (ja) 2016-10-27
CN103550195A (zh) 2014-02-05
AU2016266058A1 (en) 2016-12-22
AU2019219818A1 (en) 2019-09-12
MX2008016133A (es) 2009-01-15
EP2959894A1 (en) 2015-12-30
AU2018202210A1 (en) 2018-04-26
CN101478961A (zh) 2009-07-08
EP2959894B1 (en) 2022-10-12
KR20210010956A (ko) 2021-01-28
US9187405B2 (en) 2015-11-17
PL2959894T3 (pl) 2022-11-14
HUE059922T4 (hu) 2024-05-28
DK2959894T3 (da) 2022-10-17
JP2025016462A (ja) 2025-02-04
HK1214758A1 (en) 2016-08-05
EP2037906A1 (en) 2009-03-25
EP2698154A1 (en) 2014-02-19
PT2959894T (pt) 2022-10-18
JP6931019B2 (ja) 2021-09-01
AU2011201844B2 (en) 2012-10-25
AU2011201844A1 (en) 2011-05-19
AU2007264031C1 (en) 2016-12-15
AU2007264031B2 (en) 2011-01-27
JP2021035955A (ja) 2021-03-04
KR20170138583A (ko) 2017-12-15
HUE059922T2 (hu) 2023-01-28
SI2959894T1 (sl) 2022-11-30
KR20090024281A (ko) 2009-03-06
AU2013200356A1 (en) 2013-02-14
WO2008000419A1 (en) 2008-01-03
AU2013200356B2 (en) 2016-09-29
BRPI0713985A2 (pt) 2012-11-20
JP2013166761A (ja) 2013-08-29
JP2019167352A (ja) 2019-10-03
EP3797765A1 (en) 2021-03-31
JP2023098949A (ja) 2023-07-11
AU2021202395A1 (en) 2021-05-20
DE15177166T1 (de) 2022-01-27
HUE15177166T1 (hu) 2022-05-28
PL15177166T1 (pl) 2022-03-07
MX2022008950A (es) 2022-08-11
CA2653569A1 (en) 2008-01-03
DK2959894T1 (da) 2021-12-20
RU2617502C2 (ru) 2017-04-25
RU2569732C2 (ru) 2015-11-27
KR20150122812A (ko) 2015-11-02
US20100168078A1 (en) 2010-07-01
AU2007264031A1 (en) 2008-01-03
RU2009102278A (ru) 2010-08-10
MX2019012750A (es) 2020-02-03
CN101478961B (zh) 2013-11-27
US8741963B2 (en) 2014-06-03
JP2018109018A (ja) 2018-07-12
JP2009541386A (ja) 2009-11-26
US20110237682A1 (en) 2011-09-29
JP7258832B2 (ja) 2023-04-17
LT2959894T (lt) 2022-11-10

Similar Documents

Publication Publication Date Title
GB0612721D0 (en) Organic compounds
JOP20210187A1 (ar) تركيبات تشتمل على معدلات مستقبل سفينجوزين 1 فوسفات (s1p)
WO2009051670A3 (en) Oxylipin compounds for the treatment of ophthalmic conditions
CL2007002424A1 (es) Compuestos derivados de isoxazolidina; composicion farmaceutica que comprende a dicho compuesto, util para el tratamiento de trastornos asociados con hiperproliferacion como cancer.
CR20110169A (es) Compuestos de pirrol
WO2008059370A3 (en) Substituted bicyclocarboxyamide compounds
CL2008000322A1 (es) Proceso para la preparacion de un compuesto derivado de 2-tiazol-2-il-quinolina; compuestos intermediarios; y proceso de preparacion de dichos compuestos intermediarios.
MX2009006252A (es) Sal de tanato de rasagilina.
MX2009006481A (es) Derivados de imidazol 1-sustituidos, y su uso como inhibidores de la sintasa de aldosterona.
UA95296C2 (uk) Конденсовані циклічні сполуки
WO2011023582A3 (de) Verwendung von 1,3-diolen als biozide
AU2008303600A8 (en) 1,1,1-trifluoro-2-hydroxy-3-phenylpropane derivatives
DK2190426T3 (da) Griseofulvin-analoger til behandling af cancer ved hæmning af centrosomal clusterdannelse
WO2007138282A3 (en) Bi-aryl or aryl-heteroaryl substituted indoles
WO2010129918A8 (en) Triptolide prodrugs
MX2010004669A (es) Proceso para la preparacion de derivados de isoindol asi como tambien un proceso para la preparacion de sus intermediarios.
GB0521508D0 (en) Organic compounds
WO2008050199A3 (en) Substituted phenylmethyl bicyclocarboxyamide compounds
CL2007001919A1 (es) Compuestos derivados de 18-metil-15b,16b-metilen-19-nor-20-espirox-4-en-3-onas; composicion farmaceutica que comprende a dichos compuestos, utiles como anticonceptivos.
MY148098A (en) Quinolone compound and pharmaceutical composition
MX2009004991A (es) Derivados de monoacetato de ciclopenteno-diol.
MY150776A (en) Combination of a bis-thiazolium salt or a precursor thereof and artemisinin or a derivative thereof for treating acute malaria
WO2007054100A3 (en) Lna nucleoside phosphoramidates
MY153768A (en) Use of anti-bacterial compounds having an anaesthetic effect
MX2010002523A (es) Compuestos de piperidinilamino-tieno[2,3-d] pirimidina para tratar la fibrosis.

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)